Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
PB Fintech stock tanks 7% after Morgan Stanley downgrade to 'underweight' forecasting 25% downside
Looking ahead, Morgan Stanley expects PB Fintech's stock to de-rate as core new business performance moderates in FY26.
Morgan Stanley stock underperforms Friday when compared to competitors
Morgan Stanley closed $12.79 short of its 52-week high ($136.24), which the company achieved on November 25th.
bankingdive3d
Dive Deposits: Morgan Stanley’s MD promotions don’t set records, they follow the herd
While Citi, BofA and Goldman touted their biggest cohorts of managing directors in years, Morgan Stanley elevated greater ...
Morgan Stanley sees Aditya Birla Capital share price rallying up to Rs 247; stock rises 3.5%
Aditya Birla Capital shares rose 3.5% after Morgan Stanley upgraded the stock to 'overweight' with a target price of Rs 247, ...
Alcohol-Free Guinness Won’t Shield Diageo, Says Morgan Stanley
The popularity of alcohol-free Guinness won’t protect the shares of its owner Diageo Plc from the growing trend toward health ...
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
AB Capital shares climb 2% on Morgan Stanley's "overweight" upgrade, predicts over 40% upside
Morgan Stanley upgraded AB Capital to "overweight" from "equal-weight" and set a target price of Rs 247 per share ...
$1.2 Billion Morgan Stanley Team Thinks Dividend Investing Could Be Myopic
Robert Chen and his team like strategies like direct indexing because they systematically tax loss harvest throughout the ...